Theranos CEO Elizabeth Holmes Defends Her Company at WSJ Conference

Embattled Theranos chief executive Elizabeth Holmes took the stage at the Wall Street Journal’s WSJDLive conference to answer questions the publication raised about her blood-testing startup.

The Palo Alto company set out to revolutionize the blood-testing industry with a technology it claims could perform some 240 tests, ranging from cholesterol to cancer, from a tiny vial of blood. Investors poured $400 million into the startup, giving it a $9 billion valuation.

A recent Journal investigation challenged those claims, reporting that Theranos’s own lab equipment was handling only a fraction of the tests it sold to consumers. Sources also questioned the accuracy of the results.

Theranos has subsequently stopped collecting blood samples for all but one of its tests as U.S. Food and Drug Administration officials conducted an inspection of its facility and the Centers for Medicare and Medicaid Services, the main regulator of clinical labs, conducted an audit.

Here’s the archive of our liveblog:

This article originally appeared on Recode.net.

Will you join us?

Our biggest supporters are our readers — and we’re so grateful to everyone who has made a contribution during our September campaign. We’re less than 1,000 contributions away from reaching our goal for the month, which in turn will allow us to say yes more often when our incredible journalists come to us with questions they want to answer and projects they want to pursue. Will you make a contribution before the month ends and support our policy coverage through 2024 and beyond?

One-Time Monthly Annual

$5/month

$10/month

$25/month

$50/month

Other

$

Yes, I'll give $5/month

Yes, I'll give $5/month

We accept credit card, Apple Pay, and Google Pay. You can also contribute via